Bladder Cancer Clinical Trial
Official title:
Randomised Controlled Trial of Open Versus Laparoscopic Radical Cystectomy at a Laparoscopic Naive Center
Verified date | April 2021 |
Source | Cairo University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is a prospective randomised controlled study of urinary bladder cancer patients presented to urology unit at National Cancer Institute; Cairo University.
Status | Completed |
Enrollment | 60 |
Est. completion date | December 30, 2020 |
Est. primary completion date | July 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years to 80 Years |
Eligibility | Inclusion Criteria: - Patients with transitional cell carcinoma, squamous cell carcinoma and urinary bladder adenocarcinoma. - Patients fit for surgery (ECOG Performance Status 0,1). Exclusion Criteria: - Patients with medical comorbidities that preclude surgical management or minimally invasive techniques. - Patients with advanced hydronephrosis or renal failure. - Patients refusing surgery. - Patients with urinary bladder cancer invading bladder neck or prostatic urethra. - Patients with metastatic urinary bladder cancer. - Patients who received prior pelvic radiotherapy. - Patients refusing randomization and/or participation in the trial. |
Country | Name | City | State |
---|---|---|---|
Egypt | National Cancer Institute | Cairo |
Lead Sponsor | Collaborator |
---|---|
Cairo University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Operative time | OR time as measured in minutes, divided into time required to perform the cystectomy, lymph node dissection, and urinary diversion. | During surgery | |
Primary | Blood loss | EBL as measured in millilitres, including the effluent from the suction canister as well as estimates of the gauze swabs. | During surgery | |
Primary | Length of hospital stay | LOS as measured in days | Immediate post-operative period. | |
Primary | Time to oral intake | Measured in days | Immediate post-operative period | |
Primary | Conversion rate | Rate of conversion from laparoscopy to open surgery | During surgery | |
Primary | Re-admission rate. | Re-hospitalization requirement. | Intra-operative to sixth months. | |
Primary | Opioid requirements. | Requirement, dose and duration of narcotic analgesia. | During surgery through first post-operative week. | |
Primary | Visceral injury | Any organ injury encountered during the operation. | During surgery | |
Primary | Urine leak | Leakage of urine from urinary enteric anastomosis | Up to 4 weeks | |
Primary | Wound dehiscence, infection. | Wound gaping, evisceration or infection. | Up to 4 weeks | |
Primary | Enteric fistula | Leakage of intestinal contents due to failure of entero-enteric anastomosis | Up to 4 weeks | |
Primary | Sepsis | Infection triggering a systematic immune response | Up to 4 weeks | |
Primary | Venous thromboembolism | DVT or pulmonary embolism | Up to 2 months | |
Secondary | pT stage | Pathologic tumor stage (Stage 1, stage 2, stage 3 or stage 4) | Within 10 days post surgery. | |
Secondary | Lymph node retrieval | Number of lymph nodes retrieved by open versus laparoscopic approaches. | Within 10 days post surgery. | |
Secondary | pN stage | Lymph node metastasis (positive or negative), and number of positive nodes if present. | Within 10 days post surgery. | |
Secondary | Surgical margins | Positive margins or negative margins. Location of positive margins (Urethral, ureteric) | Within 10 days post surgery | |
Secondary | Histological grade | Low grade, intermediate grade or high grade | Within 10 days post surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06034015 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04235764 -
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
|
||
Completed |
NCT02371447 -
VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04081246 -
Transurethral Modified En Bloc Resection For Large Bladder Tumours.
|
N/A | |
Recruiting |
NCT06059547 -
Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
|
Phase 2 | |
Terminated |
NCT04779489 -
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
|
N/A | |
Not yet recruiting |
NCT04493489 -
Propranolol Adjuvant Treatment of Bladder Cancer
|
Phase 2 | |
Completed |
NCT03520231 -
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
|
Phase 2 | |
Recruiting |
NCT04537221 -
Nordic Cystectomy Study III - Transfusion
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05562791 -
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer
|
Phase 1 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT02781428 -
To Detect the Sensitivity of the UroMark Assay
|
||
Recruiting |
NCT04738630 -
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03978624 -
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
|
Phase 2 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A |